Study supports use of telomerase inhibitors for treatment of childhood cancers
Geron Corporation announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat, currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin. "Cancers of the brain and nervous system are the most common solid tumors in children and the leading cause of morbidity and death from pediatric cancers. These preclinical data show that imetelstat specifically targets the cancer stem cells in pediatric neural tumors, which we believe may be responsible for progression and recurrence of the disease," said Stephen M. Kelsey, M.D., Geron's executive vice president and chief medical officer, oncology. More
A childhood cancer is different from adult cancers
Santa Barbara Independent Share
The study suggests that there are far fewer mutations present in some childhood cancerous tumors than in tumors of adult cancers. This could have significant implications for not only how we approach and treat childhood cancers, but how we treat combat cancers in general. The study was a large collaborative effort involving 20 different medical institutes, cancer centers, and universities in the U.S. that looked at the genetics of a very aggressive brain cancer found primarily in children called medulloblastoma. More
Nurse practitioners not heading into pediatrics in anticipated
numbers, study says
Nurse practitioners, as well as physician assistants, are not yet going into pediatrics in numbers needed to support plans for incorporating those roles into the pediatric health care work force. That conclusion arose from four coordinated studies of nurse practitioners and physician assistants for the journal Pediatrics. More
Fatal medication errors seen with high-dose morphine oral solution
Medscape Medical News Share
In response to reports of serious adverse events and deaths that have resulted from accidental overdoses of morphine oral solution, 100 milligrams/5 milliliters (20 milligrams/ milliliters), Roxane Laboratories has notified health care professionals of changes in the product label and package, the U.S. Food and Drug Administration announced. More
FDA approves Orphan drug fidaxomicin for pediatric CDI
The FDA Orphan Drug Designation is intended to support the clinical development of drugs for diseases and conditions that affect fewer than 200,000 people in the United States. Orphan Drug Designation gives seven years of market exclusivity for the designated indication in the U.S. from the date the product receives marketing approval for that indication. Orphan Drug Designation also provides access to regulatory support from the FDA throughout the development process, potential grant funding for clinical studies, potential FDA fee reductions, and tax credits related to development expenses. This designation does not imply that fidaxomicin has demonstrated the efficacy, safety and quality required for drug approval in the U.S. More
Single rooms affect ICU infection rate
MedPage Today Share
Switching to private rooms in the intensive care unit (ICU) may help reduce health care-associated infections, researchers found. After a single ICU changed from multibed rooms to single rooms, the combined rate of acquisition of three common exogenous organisms — Clostridium difficile, vancomycin-resistant Enterococcus species, and methicillin-resistant Staphylococcus aureus (MRSA) — dropped by 54 percent. More
End-of-life counseling sound and humane policy
The Oklahoman Share
The new rule on end-of-life counseling simply allows doctors to charge for voluntary advance care planning. Under the rule, doctors can provide information to patients on how to prepare an advance directive, stating how aggressively they wish to be treated if they're so sick that they can't make health care decisions for themselves. This is not a "death panel." It's just a conversation with your doctor, if you want it. A law passed in 2008 included voluntary end-of-life planning discussions during orientation visits for new Medicare beneficiaries. The new regulation simply extends this benefit to annual wellness visits created by the health care reform law. More
Rituximab extends survival in lymphoma, but ups risk of
Medscape Medical News Share
The addition of rituximab to high-dose chemotherapy and autograft is effective in patients with high-risk lymphoma. But adding rituximab does have a downside: Increased risk of secondary solid tumors. That's according to results from a study that appears in the Journal of Clinical Oncology. Overall survival was 16.2 years. The cumulative incidence of secondary myelodysplasia and acute leukemia at 5 and 10 years was approximately 3.0 percent and 4.5 percent. The incidence of solid tumors was 2.5 percent to 6.8 percent. More
CMS requires hospitals to report bloodstream infections in ICUs
American Medical Association Share
With the new year came a new requirement that hospitals start reporting the number and rate of adult patients in their intensive care units who acquire central line-associated bloodstream infections or else lose 2 percent in Medicare pay. The catheter-related bloodstream infections kill an estimated 31,000 people annually and have been the focus of successful statewide quality initiatives using infection-prevention checklists, said the Centers for Disease Control and Prevention. The surgical infections that hospitals will have to start reporting in 2012 are those that arise in adult and pediatric patients after coronary artery bypass graft, hip or knee arthroplasty, colon surgery, hysterectomy and vascular surgery. More
APHON Webinar: Let's Talk about Sex!
Developing Patient Education Materials about Sex for Teens and Young Adults with Cancer
Thursday, January 20, 2011
1 p.m. (EST)
Members: $49 (per site) Nonmembers: $129 (per site)
Speakers Janie Teresa Lappan, MEd BScN RN CPHON™ and Lindsay Wizowski, MEd BScN of the interdisciplinary pediatric oncology team at McMaster Children's Hospital will present evidence-based, patient-centered, patient education materials for teens and young adults regarding sex and sexuality. The need for these patient education materials was identified after an incidental finding of pregnancy during routine follow up scans on a 15 year old cancer patient. When a review of the literature and existing patient education materials was conducted, they found a lack of available information pertaining to sex and sexuality specific to teens and young adults with cancer.
The materials to be presented are intended for nurses and health professionals, and students in the health disciplines to help facilitate discussion about sex and sexuality between health care professionals and teens and young adults. The Webinar will present 60 minutes of educational content and 15 minutes of Q & A time.
CE: For an additional $15 fee, attendees of this Webinar are eligible to receive 1.5 nursing contact hours by listening to the program and successfully completing an online posttest and evaluation. For those people who are not able to participate in the live Webinar, there will be an opportunity to watch the Webinar once it is posted online and still receive the CE after purchasing the posttest for $15.
The Association of Pediatric Hematology/Oncology Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.